Millions of Medicare Part D enrollees who depend on treatments for cancer, diabetes, and asthma will pay sharply less starting January 1, 2027, after the Centers for Medicare and Medicaid Services locked in negotiated prices on 15 high-cost drugs. The reductions range from 38% to 85% off prior prices, covering widely prescribed medicines including Ozempic and several cancer pills. This second cycle of the Medicare Drug Price Negotiation Program represents the largest batch of drugs to receive maximum fair prices so far, expanding from the 10 drugs negotiated in the first round.
Lower copays for 15 drugs starting January 2027
The price cuts matter right now because they translate directly into lower out-of-pocket costs at the pharmacy counter. When CMS sets a maximum fair price, that ceiling flows through to beneficiary cost-sharing. For someone filling a monthly cancer prescription that previously cost hundreds of dollars in copays, an 85% reduction changes the math on whether they can afford to stay on treatment.
CMS selected these 15 drugs across several major conditions based on Part D spending data and how many beneficiaries use each product. The agency’s selection process follows statutory factors spelled out in the Social Security Act, specifically sections 1191 through 1198, which require CMS to weigh clinical value, research and development costs, and market data when making its initial price offer. That framework is designed to focus negotiations on drugs that drive the highest Medicare spending while still recognizing their therapeutic importance.
Because these are Part D drugs, the impact will be felt most immediately in monthly copays and coinsurance. Beneficiaries who take oral oncology medicines, inhalers for severe asthma, or injectable diabetes therapies could see their pharmacy bills fall by dozens or even hundreds of dollars per fill. Plan sponsors will be required to honor the maximum fair price, and pharmacies will process claims using the reduced amounts, so the lower prices should appear automatically at the point of sale.
A key question is whether cheaper prices will shift prescribing patterns. If a negotiated drug costs significantly less than a therapeutic alternative that was not selected for negotiation, patients and physicians have a financial reason to favor the negotiated option. Claims data from 2027 and 2028 could show a measurable increase in new prescriptions for these 15 drugs relative to competitors in the same therapeutic class. That shift would be driven by economics, not by any change in clinical guidelines, and it would signal that the negotiation program is reshaping market dynamics beyond simple cost reduction.
The ripple effects may extend to plan formularies as well. Part D plans routinely adjust tier placement, prior authorization rules, and preferred drug lists based on net prices. Once the negotiated ceilings take effect, plans will have an incentive to move these products into more favorable tiers, which could further reduce out-of-pocket costs and make it easier for patients to access the negotiated drugs without extra paperwork or delays.
Statutory framework and enforcement behind the price cuts
The negotiation authority comes from the Inflation Reduction Act, codified in 42 U.S.C. Part E. That statute sets annual selection counts: 10 drugs for 2026, 15 for 2027 and 2028, and 20 for 2029 onward. CMS published the full list of selected drugs and prices in machine-readable files, including per-drug explanations of the data inputs and negotiation steps behind each maximum fair price. Those technical documents outline how CMS considered clinical benefit, unmet need, and available generic or biosimilar competition when determining the final amounts.
Manufacturers that refuse to participate face steep consequences under the law, including the prospect of substantial excise taxes on sales of the affected drugs. CMS has emphasized that the negotiation program is mandatory for companies whose products are chosen, and the agency has built processes for monitoring compliance and calculating penalties if firms decline to sign agreements or fail to honor the negotiated ceilings in their dealings with Part D plans.
To date, drugmakers have largely opted into the process. CMS reported broad manufacturer participation in the second cycle, meaning the 15 newly selected drugs will move forward to implementation in 2027 rather than being tied up by noncompliance sanctions. That level of engagement suggests companies are choosing to negotiate within the statutory framework rather than test the enforcement provisions in court or absorb escalating tax liabilities.
Looking ahead, the mechanics used in this second cycle will serve as a template for future rounds as more drugs age into eligibility. Each year’s selections will build on the prior ones, gradually extending negotiated prices to a larger share of Part D spending. For beneficiaries, the most visible change will remain straightforward: lower, more predictable pharmacy bills for some of the costliest and most widely used medicines in Medicare.
Free tool for readers: You check your blood pressure — when did you last check your retirement? You can get your free Retirement Safety Score in about five minutes, with no sign-up to see it.
